BioStock: Strengthened finances and clinical progress for BioInvent in Q3

The third quarter 2022 report released by biotech company BioInvent focuses on the strong cash position of a total of over SEK 1.6 billion, as well as the five ongoing projects in clinical development. According to CEO Martin Welshof, the company has created a solid foundation for significant upcoming clinical milestones.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/11/strengthened-finances-and-clinical-progress-for-bioinvent-in-q3/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/